• Molecular NameVincristine
  • Synonym22-Oxovincaleukoblastine; Indole alkaloid; LCR; Leurocristine; VCR; VIN; Vincristina [DCIT]; vincristine; Vincristine Sulfate; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Z-D-Val-Lys(Z)-OH
  • Weight824.972
  • Drugbank_IDDB00541
  • ACS_NO57-22-7
  • Show 3D model
  • LogP (experiment)2.8
  • LogP (predicted, AB/LogP v2.0)3.08
  • pka5.0, 7.4
  • LogD (pH=7, predicted)2.59
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.41
  • LogSw (predicted, AB/LogsW2.0)6.62
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors3
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds10
  • TPSA171.17
  • StatusFDA approved
  • AdministrationExclusively intravenous
  • PharmacologyA vinca alkaloid from the Catharanthus roseus (Madagascar periwinkle), formerly Vinca rosea and hence its name. It is a mitotic inhibitor, and is used in cancer chemotherapy.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding75.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized by CYP3A and excreted unchanged into bile (substrate for P-glycoprotein).
  • Half life22.6 h
  • ExcretionMostly biliary, 10% in urine
  • Urinary Excretion10~20
  • CleranceN/A
  • ToxicityIVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
  • LD50 (rat)N/A
  • LD50 (mouse)N/A